The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and PfizerZacks Investment Research • 01/03/25
Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend StocksThe Motley Fool • 12/24/24
Johnson & Johnson (JNJ) Ascends But Remains Behind Market: Some Facts to NoteZacks Investment Research • 12/23/24
Dow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks Now24/7 Wall Street • 12/19/24
Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To BuySeeking Alpha • 12/18/24
Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplantGlobeNewsWire • 12/18/24
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 12/16/24